Embolization Proves Its Mettle for Subdural Hematoma

PHOENIX — For power or subacute subdural hematoma, embolization of the heart meningeal artery (MMA) diminished recurrence, three randomized trials confirmed.

Two trials with the Onyx liquid embolic machine and one with the Squid liquid embolic machine had been reported with what one presenter known as “very consistent” findings at the closing gradual-breaking science session of the American Stroke Affiliation World Stroke Conference.

The means has been musty sporadically off-ticket for subdural hematoma, even supposing familiar to neurointerventionalists attributable to use in dural arteriovenous fistulas and arteriovenous malformation, current session co-moderator Tudor G. Jovin, MD, of the Cooper Neurological Institute in Camden, New Jersey.

“That is tall data, these three trials, on legend of they are establishing this scheme as a same old of care,” he advised MedPage On the unusual time. “Level one proof used to be lacking, and I feel this would possibly possibly increasingly possible well change apply and change guidelines.”

“I’d scheme the analogy with the thrombectomy trials of 2015. There had been some facilities that had been doing it, but it wasn’t the same old of care,” he said. “Or not it would be as impactful because the 2015 trials had been for thrombectomy.”

Surgical remedy with craniotomy or by drilling a burr hole to drain the hematoma appears to had been in use for hundreds of years, in step with archaeological proof. Conservative scientific management with therapies esteem tranexamic acid administration, steroids, or statins is standard as effectively.

Alternatively, post-surgical recurrence charges are up to 20% in many series. A fresh systematic overview confirmed a 36% nonsuccess rate for conservative remedy.

“As that fluid has accumulated on the surface of the mind, you tend to build membranes,” current Jason Davies, MD, PhD, of the Express College of New York at Buffalo. “You comprise inflammatory cells that stretch in which comprise a reliable-angiogenic position. You start to get ingrowth of neovascularity from the overlying dura, and these vessels tend to be somewhat poorly fashioned and to be leaky. And so what occurs is that these membranes start having repeated microhemorrhages, fluid exudates, and they truly snatch on a lifestyles of their very comprise.”

“So the conception is, if we can devascularize these membranes by interrupting the blood vessels, we can dry up the membranes, interrupt that cycle, and with any luck in the cut price of the recurrence charges and beef up scientific outcomes for the affected person,” he outlined.

Onyx Outcomes

Davies reported intervening time outcomes from the EMBOLISE trial cohort present process surgical management. The trial — designed to toughen an application to the FDA for an expanded indication — also has an arm that randomized sufferers who elected conservative management with out surgical treatment; that data will possible be reported at a later date.

Within the surgical cohort, subdural hematoma recurrence or progression requiring surgical drainage by scheme of 90 days occurred in 4.1% of sufferers randomized to embolization with the Onyx liquid embolization machine, when put next with 11.3% treated with surgical treatment on my own (RR 0.36, 95% CI 0.11-0.80, P=0.0081).

The number desired to take care of used to be about 14, or right 12 in a modified intent-to-take care of study excluding for sufferers treated outdoors the protocol.

Deterioration in neurologic characteristic used to be same between groups (11.9% and 9.8%, respectively, P=0.0022 for non-inferiority).

The surgical cohort in the trial included 400 sufferers at 60 facilities all over the U.S. Inclusion criteria required a premorbid modified Rankin Rating (mRS) of 0-3, analysis of subacute or power subdural hematoma on MRI or CT imaging with corroborating scientific symptoms, and traits that ruled out observation on my own. Radial access and native anesthesia had been impressed for the scheme.

All embolization procedures achieved technical success for the aim vessel, with 1.1% reflux to non-purpose vessels. Severe harmful events (AEs) connected to the embolization scheme occurred in 2% of sufferers inner 30 days, but none of the four cases had been deemed connected to Onyx.

Neurologic demise in the indispensable 90 days had been bigger than twice as standard in the embolization body of workers (4.6% vs 2.0%), but with regards to all had been attributable to the subdural hematoma with out any connected to Onyx or the embolization scheme. No ipsilateral visible complications or predominant intracerebral hemorrhage connected to Onyx or the embolization scheme occurred both.

One limitation used to be about 10% of neglected health center visits at 90-day apply-up given the timing of the trial all over the COVID-19 pandemic (December 2020 to August 2023) with a pretty extinct, aged population. The typical age used to be spherical 71 in the gape.

“We predict about MMA embolization desires to be regarded as an adjunct for sufferers who undergo surgical drainage of power or subacute subdural hematomas,” concluded co-presenter Jared Knopman, MD, of Weill Cornell Medication in New York Metropolis. “We’re very infected by these outcomes.”


A second trial from China, MAGIC-MT, also confirmed a 4.93-share point cut price in symptomatic recurrence or progression of subdural hematoma or demise inner 90 days after randomization to MMA embolization using Onyx when put next with in the neighborhood obvious care management on my own (7.2% vs 12.2%, P=0.02).

Ying Mao, MD, PhD, of Huashan Scientific institution and Fudan College in Shanghai, reported that the trial included 727 symptomatic non-acute subdural hematoma sufferers with a shift in midline construction or deformation of native cerebral cortex. It had inclusion criteria similar to the EMBOLIZE trial, Mao current. It likewise allowed native doctors to attain to a resolution on conservative management or burr hole drainage, however each groups had been randomized into the same trial cohort, unlike EMBOLIZE.

Symptomatic subdural hematoma recurrence (maximum thickness >10 mm) or re-operation inner 90 days used to be numerically much less standard with embolization in the 78% of sufferers who underwent burr-hole drainage (4.7% vs 5.2%).

For these managed conservatively, symptomatic subdural hematoma progression confirmed a increased impact of embolization, with charges of 1.7% versus 4.7%. Different elements connected with a increased remedy originate had been known head trauma, smaller midline shift, and smaller hematoma volume.

Safety findings truly confirmed greatly fewer predominant AEs inner 90 days in the embolization body of workers (6.7% vs 11.6%, P=0.02). Embolization-connected complications occurred in 0.8% of sufferers, with one case of facial nerve paralysis and two of distinction agent allergic response.

SQUID Outcomes

A fresh liquid embolization machine, dubbed Squid, bigger than tripled the likelihood of remedy success when put next with same old management, reported Adam Arthur, MD, of Semmes-Murphey Neurological Hospital in Memphis, Tennessee, who known as the outcomes “very consistent” with what had already been presented at the gradual-breaking science session.

Embolization with Squid yielded a 15.5% failure rate inner 180 days when put next with 39.2% using same old management on my own (OR 3.60, 95% CI 1.91-6.78) when failure used to be outlined 3 methods: residual or re-accumulation to at the least a 10-mm thick hematoma, re-operation or surgical rescue, or any fresh main tournament (disabling stroke, myocardial infarction, or demise from any neurological place aside off).

Critically, sufferers who had MMA embolization alongside with conservative management truly had a lower chance of remedy failure than these who got surgical treatment on my own (19.1% vs 25.4%). The bottom chance used to be seen in these who got the mixed surgical treatment-plus-embolization strategy (12.3%), whereas fully 59.2% had failure with non-surgical management on my own.

The STEM pivotal trial randomized 310 sufferers (stratified by surgical management, which 189 elected, or non-surgical care).

Participants had been ages 30 and older and had premorbid mRS 0-1 in the prior 12 months. Their power subdural hematoma desired to be symptomatic and measure at the least 10 mm at its thickest point and exert native cortical knocking down or midline shift.

No deaths in the trial had been attributed to the scheme or instrument, and 30-day all-place aside off mortality used to be same between remedy arms. The easiest main disabling stroke occurred in the adjust body of workers.

Of the other endpoints for which data will possible be reported later, Arthur current that mRS shift, scientific institution length of address, and neurocognitive scores will possible be of particular curiosity.

“Again, we’re taking a discover at an older affected person population and making an are trying to support them to amass independence and secure cognitive competence later in lifestyles,” he concluded.

  • author['full_name']


EMBOLISE used to be backed by Medtronic.

Davies disclosed relationships with NIH, NSF SBIR, UB CAT, Buffalo Translational Consortium, Cummings Foundation, Nvidia, Google,, Rist Neurovascular, Cerebrotech, Synchron, Hyperion, Medtronic, Microvention, Crucial Care, Xenter, RapidPulse, Canon, Johnson & Johnson, and StrokeNet.

MAGIC-MT used to be supported by the Shanghai Shenkang Scientific institution Construction Heart, Shanghai Municipal Health Commission, and Covidien/Medtronic.

Mao disclosed relationships with Medtronic.

STEM used to be backed by BALT USA.

Arthur disclosed relationships with Arsenal, Cerenovus, Medtronic, Microvention, Neuros, Penumbra, Perfuze, Scientia, Siemens, Stryker, Bendit, EndoStream, Magneto, Mentice, Neurogami, Neuros, Perfuze, RevBio, Scientia, Serenity, Synchron, Tulavi, Vastrax, and

Jovin disclosed relationships with Cerenovus, Route 92, Galaxy Therapeutics, Methinks, Anaconda ,, Kandu Health, StataDX, FreeOx Biotech, Stryker, and Medtronic.

Main Source

World Stroke Conference

Source Reference: Davies JM, et al “The EMBOLISE gape: Embolization of the heart meningeal artery with onyx liquid embolic machine in the remedy of subacute and power subdural hematoma” ISC 2024; Abstract LB28.

Secondary Source

World Stroke Conference

Source Reference: Mao Y, et al “The MAGIC-MT trial: Managing non-acute subdural hematoma using liquid supplies: A Chinese randomized trial of heart meningeal artery remedy” ISC 2024; Abstract LB29.

Extra Source

World Stroke Conference

Source Reference: Arthur A, et al “STEM (The Squid trial for the embolization of the MMA for the remedy of CSDH)” ISC 2024; Abstract LB31.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button